Atlas Venture is a leading biotech venture capital firm.  Atlas companies are custom built to realize their scientific and business potential.

DISCOVER: Identifying true innovation from high-impact science.

DERISK: Proving and maturing the science and technology to guide clinical translation

SHAPE: Crafting the right business model for each opportunity.

STRENGTHEN: Rolling up our sleeves to position our companies for successful drug development and exits in all market environments.

TypeInvestor
HQCambridge, US
Founded1984
Websiteatlasventure.com
Atlas Venture was founded in 1984 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Atlas Venture

Peter Barrett

Peter Barrett

Partner
David Grayzel

David Grayzel

Partner
Jason Rhodes

Jason Rhodes

Partner
Jean-Francois Formela

Jean-Francois Formela

Partner
Bruce Booth

Bruce Booth

Partner
Kevin Bitterman

Kevin Bitterman

Partner
Show more

Atlas Venture Office Locations

Atlas Venture has an office in Cambridge
Cambridge, US (HQ)
400 Technology Square
Show all (1)
Report incorrect company information

Atlas Venture News and Updates

Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture

CAMBRIDGE, Mass., Sept. 27, 2018 /PRNewswire/ -- Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced the closing of a $30 million Series A financing led by F-Prime Capital...

Atlas Venture wraps up 11th fund at $350 mln

Cambridge, Massachusetts-based Atlas Venture, an early-stage venture firm, has closed its oversubscribed 11th fund at $350 million. Altas Ventures invests in biotech startups.
Report incorrect company information

Atlas Venture Blogs

Targeting Aging Comes Of Age

We finally are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new therapies actionable for the first time. This blog is written by Tom Hughes, CEO of Navitor Pharma, as part of the From The Trenches feature of LifeSciVC. Read more. The post Ta…

Bring Your A-Game for BD

As with most professions – especially those that involve longer-term outcomes – the way people get good at BD is with experience. So, I’d like to share some of my experiences doing BD from various vantage points, with the hope that it might help you jump start the career of anyone interested in BD. …

Fear Of The Flood: Post-IPO Lockup Expiry In Biotech

The dreaded “lockup expiry” is something all newly-minted public biotechs begin to worry about shortly after their offerings. The fear seems reasonable: venture investors and other large shareholders, now free to trade, dump large amounts of stock into the market quickly, creating significant downwa…

Biotech Climate Change

When I first moved from the UK to the US, I told my parents that there was more biotech VC investment in Cambridge, MA each quarter than there was in the whole of the UK in a year. Since then, my mother has been cutting ‘biotech is booming’ articles out of British newspapers to temptRead More » The …

Atlas, F-Prime provide launch money for Akrevia — a little biotech with big plans to design better drugs

A couple of veteran drug developers are guiding a stealthy startup dubbed Akrevia Therapeutics out into the open today after a pair of high-profile biotech investors blessed the operation with a $30 million launch round. Read more. The post Atlas, F-Prime provide launch money for Akrevia — a little …

The Rising Tide Of Biotech IPO Valuations

The biotech IPO market continues to march forward, with five new offerings expected to price in the next week or so. Investor demand for stories advancing novel innovative therapies remains at historic levels – extending what is now over a six-year window for biotech IPOs. Read more. The post The Ri…
Show more

Atlas Venture Company Life and Culture

Report incorrect company information